Four weeks ago, after a Houston judge denied J&J’s third attempt to resolve approximately 90,000 talcum powder lawsuits ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that has plenty of competition. The human Fc receptor ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Could a discovery in scanning enable psychiatrists to spot the neurological causes of depression in patients' brains and ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

The federal government has bankrolled the use of an artificial ketamine nasal spray to combat treatment-resistant depression, ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other value stocks in Ken Fisher’s portfolio. Trump’s “stupid” tariffs will fail ...

Johnson & Johnson has shifted its generative AI strategy away from broad experimentation across the healthcare conglomerate to a more focused approach. Chief Information Officer Jim Swanson said ...